Top Highlights From the 2016 ASCO GU Cancers Symposium

References:

1. Lee WR, Dignam JJ, Amin M, et al. NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 1.

2. Dearnaley DP, Syndikus I, Mossop H, et al. Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016). Presented at the 2016 Genitourinary Cancers Symposium. Abstract 2.

3. Shipley WU, Pugh SL, Lukka HR, et al. NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 3.

4. Scher HI, Graf R, Louw J, et al. Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 163.

5. Abel EJ, Zargar K, Margulis V, et al. Role of cytoreductive nephrectomy in renal cell cancer (RCC) with venous tumor thrombus. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 496.

6. Motzer RJ, Sharma P, McDermott DF, et al. CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).  Presented at the 2016 Genitourinary Cancers Symposium. Abstract 498.

7. Escudier BJ, Motzer RJ, Powles T, et al. Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Presented at the 2016 Genitourinary Cancers Symposium. Abstract 499.